Lesson plan

Adegramotide

Adegramotide (DSP-7888) is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme. It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials. As of , phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion (DSP-7888) in combination with Bevacizumab. The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of , is still continuing as planned.

Back to article

Article summary

Adegramotide (DSP-7888) is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme. It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials. As of , phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion (DSP-7888) in combination with Bevacizumab. The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of , is still continuing as planned.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.